Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.
Часто задаваемые вопросы
В каком секторе работает Coeptis Therapeutics Holdings Inc (COEPW)?
Coeptis Therapeutics Holdings Inc относится к сектору Здравоохранение.
Какова текущая цена акций Coeptis Therapeutics Holdings Inc (COEPW)?
По последним данным, цена акций Coeptis Therapeutics Holdings Inc составляет 0,01 $, предыдущее закрытие — 0,01 $.
Выплачивает ли Coeptis Therapeutics Holdings Inc (COEPW) дивиденды?
Нет, Coeptis Therapeutics Holdings Inc не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Coeptis Therapeutics Holdings Inc (COEPW)?
У компании Coeptis Therapeutics Holdings Inc бета -0.590, что указывает на более низкую волатильность по сравнению с рынком в целом.
